Idorsia Pharmaceuticals Ltd. supported the development of this volume of the Frontiers of Neurology and Neuroscience book series (Vol. 45; Series Editor: J. Bogousslavsky, Montreux).

The Guest Editors declare that during the development of the book, Michel A. Steiner and Martine Clozel were employed by Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, and that Professor Yanagisawa, an independent researcher (Director and Professor of the International Institute for Integrative Sleep Medicine [WPI-IIIS], University of Tsukuba, Ibaraki, Japan) received consultancy fees from Idorsia Pharmaceuticals Ltd.

Editorial assistance for the development of the book was provided by Jessica Beake (Beake Medicom), funded by Idorsia Pharmaceuticals Ltd.

Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and MEDLINE/Pubmed.

This publication is listed in bibliographic services, including Current Contents® and MEDLINE/Pubmed.

Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. The authors, the editors, and the publisher have made every effort to obtain permission for all copyright-protected material. Any omissions are entirely unintentional. The publisher would be pleased to hear from anyone whose rights have unwittingly been infringed.

© Copyright 2021 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
www.karger.com
Printed on acid-free and non-aging paper (ISO 9706)
ISSN 1660–4431
eISSN 1662–2804
ISBN 978–3–318–06843–6
e-ISBN 978–3–318–06844–3

The copyright of each individual book chapter is held by the author(s) of the respective chapter. Each individual chapter is licensed under a Creative Commons Attribution-NonCommerical-No Derivative 4.0 International License (CC BY-NC-ND 4.0). Any use of a book chapter in whole or in parts, in any way that is not covered by the applicable license, requires permission in writing by S. Karger AG.

Idorsia Pharmaceuticals Ltd and its affiliates have a license to use this work.